Daunorubicin-Cytarabine Liposome
Cytarabine-daunorubicin (CPX 351) is a Liposomal formulation prepared from Cytarabine (HY-13605) and Daunorubicin (HY-13062A) at a fixed synergistic molar ratio of 5:1. Cytarabine-daunorubicin improves secondary acute myeloid leukemia. Cytarabine-daunorubicin can be used in research related to secondary acute myeloid leukemia, high-risk myelodysplastic syndrome, and chronic myelomonocytic leukemia.
For research use only. We do not sell to patients.
- CAS No.: 1256639-86-7
- Formula: C36H42N4O15
- Molecular Weight:770.74
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Cytarabine-daunorubicin is 5 times more potent against FLT3-ITD leukemic blasts than against wild-type leukemic blasts[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1256639-86-7
-
Molecular Weight 770.74
-
Formula C36H42N4O15
-
SMILES
OC1=C(C(C2=CC=CC(OC)=C2C3=O)=O)C3=C(O)C4=C1C[C@](C(C)=O)(O)C[C@@H]4O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O)N.O[C@H]6[C@H](O)[C@H](N7C(N=C(C=C7)N)=O)O[C@@H]6CO
-
Synonyms
CPX 351; Cytarabine-daunorubicin
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Daunorubicin-Cytarabine Liposome Related Classifications
HY-160952 Related Classifications
Powered by Bioz
- Daunorubicin-Cytarabine Liposome
- 1256639-86-7
- CPX 351
- Cytarabine-daunorubicin
- CPX351
- CPX-351
- Liposome
- Drug Derivative
- higher risk myelodysplastic syndromes
- wild-type leukemia blasts
- leukemia cells
- chronic myelomonocytic leukemia
- higher risk MDS/CMML
- normal bone marrow cells
- FLT3-ITD leukemia blasts
- secondary acute myeloid leukemia
- Inhibitor
- inhibitor
- inhibit